肿瘤细胞治疗研究
英文原题：Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
brentuximab vedotin (BV) 和 checkpoint inhibitors (CPI) 的获批彻底改变了复发/难治性经典霍奇金淋巴瘤 (cHL) 患者的治疗格局。
brentuximab vedotin (BV) 和 checkpoint inhibitors (CPI) 的获批彻底改变了复发/难治性经典霍奇金淋巴瘤 (cHL) 患者的治疗格局。近年来，这些药物迅速前移至更早的治疗线数，包括自体造血细胞移植 (auto-HCT) 后巩固治疗、HCT 前挽救治疗以及一线治疗。这一实践转变意味着双难治性（对 BV 和 CPI 均难治）cHL 正成为日益常见的临床问题。对于不适合临床试验的患者，传统细胞毒药物和靶向治疗（超说明书用药）可能是潜在选择。对于适合移植的患者，鉴于当代移植结局的显著改善，应考虑早期转诊至异基因 HCT。细胞治疗选择包括 CD30.CAR-T 细胞、Epstein-Barr 病毒导向的细胞毒性 T 细胞以及 CD16A/30 双特异性NK 细胞衔接器，这些疗法前景可期，目前正在临床试验中。
The approval of brentuximab vedotin (BV) and checkpoint inhibitors (CPI) has revolutionized the management of relapsed/refractory classical Hodgkin lymphoma (cHL) patients. In recent years these agents have rapidly moved to earlier lines of therapy, including post-autologous hematopoietic cell transplant (auto-HCT) consolidation, pre-HCT salvage, and the frontline treatment setting. This shift in practice means that double-refractory (refractory to both BV and CPI) cHL is becoming an increasingly common clinical problem. In patients who are not eligible for clinical trials, conventional cytotoxic and targeted therapies (off label) may be a potential option. In patients who are transplant eligible, early referral to allogeneic HCT should be considered given the significant improvement in transplant outcomes in the contemporary era. Cellular therapy options including CD30.chimeric antigen receptor T cells, Epstein-Barr virus-directed cytotoxic T cells, and CD16A/30 bispecific natural killer cell engagers appear promising and are currently in clinical trials.
MEMBER ACCOUNT
登录成功会直接打开下一页。
